The Food and Drug Administration plans to loosen the rules for approving new treatments for Alzheimer's disease. Drugs in clinical trial would qualify for approval if people at very early stages of the disease subtly improved their performance on memory or reasoning tests, even before they developed any obvious impairments. Companies would not have to show that the drugs improved daily, real-world functioning.
FDA plans to ease rules on approving Alzheimer's drugs
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.